Wysham, Carol <br/><br/>
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.  [electronic resource] 

 -  Diabetes, obesity & metabolism  10 2017 
 - 1408-1415 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12961  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Blood Glucose--drug effects<br/>Body Mass Index<br/>Body Weight--drug effects<br/>Diabetes Mellitus, Type 2--blood<br/>Drug Combinations<br/>Female<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemia--chemically induced<br/>Insulin Glargine--administration & dosage<br/>Male<br/>Middle Aged<br/>Peptides--administration & dosage<br/>Time Factors